Habte A.YimerMD

PubMed

• Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
  Xu, L., Shadman, M., Flinn, I., Levy, M., Porter, R., Burke, J., Zafar, S., Cultrera, J., Misleh, J., Kingsley, E., Yimer, H., Freeman, B., Chaudhry, A., Tumula, P., G...> ;Haematologica. 2024 Jan 25
• Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
  Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Keshu Zhou, Ma...> ;Future Oncology. 2024 Apr 1
• 1 citations
  In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
  Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Sudhir Manda, Roger M Lyons, Habte A Yimer, Dasha Cherepanov, Eric Lloyd, Pres...> ;Blood Cancer Journal. 2023 Sep 19
• 2 citations
  Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
  Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovan...> ;Ejhaem. 2023 Feb 1
• 78 citations
  Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
  Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Keshu Zhou, Ma...> ;The New England Journal of Medicine. 2023 Jan 26
• 1 citations
  Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity.
  W H Wilson Tang, Habte Yimer, Mohan Tummala, Spencer Shao, Gina Chung, Jessica Clement, Bong Chul Chu, Earl Hubbell, Kathryn N Kurtzman, Charles Swanton, Lewis R Roberts> ;Preventive Medicine. 2023 Feb 1
• 14 citations
  Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
  Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiř...> ;Journal of Clinical Oncology. 2023 Feb 10
• 19 citations
  Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...
  Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao...> ;The Lancet. Haematology. 2023 Jan 1
• Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.
  Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, W H Wilson Tang, Habte Yimer, Mohan Tummala> ;Tumori. 2023 Jun 1
• 7 citations
  Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
  Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke, Mohit Narang, Don Stevens, Kathleen S Gray, Yana Lutska, Padma Bobba, Keqin Qi, Daniela Hoe...> ;Leukemia & Lymphoma. 2022 Oct 1
• 15 citations
  Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
  John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, William G Wierda, Michael Y Choi, Susan M O'Brien, Mazyar Shadman, Matthew S Davi...> ;Haematologica. 2022 Apr 1
• 1 citations
  Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
  Jeff P. Sharman, John M. Burke, Habte A. Yimer, Michael Boxer, Sunil Babu, Jia Li, Yeung-Chul Mun, Alexey V. Danilov, Gibb study investigators> ;Leukemia & Lymphoma. 2021 Mar 21
• 8 citations
  Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
  Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
• 149 citations
  Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
  Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer, Richard Leblanc, Naoki Takezako, Robert Donald McCr...> ;The Lancet. Haematology. 2019 Sep 1
• 46 citations
  Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
  Habte A. Yimer, Jason M. Melear, Edward A. Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Sriya Gunawardena, Yana Lutska, Keqin Qi, Jon Ukro...> ;British Journal of Haematology. 2019 May 1
• Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...
  Alexey V. Danilov, Habte A. Yimer, Michael Boxer, John M. Burke, Sunil Babu, Jia Li, Yeung-Chul Mun, Peter Trask, Anthony Masaquel, Jeff P. Sharman> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 Dec 7
• Join now to see all

Abstracts/Posters

• Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...
  Habte A Yimer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019